Grant Award View - GA188765
Industrial biotechnology for the manufacture of alkaloid pharmaceuticals
- GA188765-V2 - Variation to Grant (25-Jan-2022 )
- GA188765-V1 - Grant Value & Contact Phone Updated (6-Oct-2021 )
Drugs that treat opioid dependence and overdose are increasingly needed but their manufacture is difficult, inefficient and expensive. This project aims to develop enzymatic N-demethylation as a simpler and more sustainable approach to the manufacture and modification of opioid antagonists, alkaloids and other drug targets. It will increase our understanding of enzymatic N-demethylation and address engineering and biotechnology challenges to improve yield and product isolation and concentration. Improvements in drug manufacturing processes will assist drug affected communities and industry will benefit from value adding, greater market share and flexibility, increased innovation and de-risked processes and new products.